Charles Esmon, PhD

Oklahoma Medical Research Foundation
825 N.E. 13th
Room A-205, Mail Box 45
Oklahoma City, Oklahoma 73104

PHONE:  (405) 271-6474

E-MAIL:  Charles Esmon

TITLES

Lloyd Noble Chair, Cardiovascular Research

Member & Head, Cardiovascular Biology Research at OMRF

Adjunct Professor, Pathology

Adjunct Professor, Biochemistry

Investigator at Howard Hughes Medical Institute

EDUCATION

University of Illinois
Urbana, Illinois
B.S. - Chemistry (1969)

Washington University
St. Louis, MO.
Ph.D. - Biochemistry (1973)

Recent Awards

  • Member, National Academy of Sciences (2002- )

  • Inaugural Member, Oklahoma Inventors Hall of Fame (2002)

Research Interests/Sub-Specialty

My research focuses on the formation of blood clots and on the natural mechanisms that prevent these clots from forming inappropriately in blood vessels. When occlusive clots form within blood vessels, strokes, heart attacks, pulmonary emboli and phlebitis result. These processes are a major cause of death and morbidity. In a different disease process, bacterial or viral infection can lead to septic shock, a condition that is often associated with massive blood clotting especially in the small vessels. Once this process occurs, it is often fatal. We have identified components of the blood vessel that prevent these processes and are attempting to understand the relationship between these components and the above disease processes. Our studies are designed to identify how the components function and their potential utility in blocking these disease processes. These questions are addressed by biophysical methods including X-ray crystallography, biochemical, immunological, molecular biological and physiological studies. Preliminary clinical results support the concept that these agents may be safe and very effective in certain forms of vascular disease. Release of these components from the vessel wall can also be used as a monitor of blood vessel disease processes.

PUBLICATIONS
Click link for abstract

  1. Rezale AR, HE X and Esmon CT. Thrombormodulin increases the rate of thrombin inhibition by BPTI. Biochemistry. 1998; 37: 693-699.

  2. Taylor FB Jr, Stearns-Kurosawa DJ, Kurowasa S, Ferrell G, Chang AC, Laszik Z, Kosanke S, Peer G and Esmon CT. The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood. 2000; 95:1680-1686.

  3. Gu JM, Fukudome K and Esmon CT. Characterization and regulation of the 5'-Flanking Region of the Murine Endothelial Protein C Receptor Gene. J Biol Chem. 2000; 275:12481-12488.

  4. Taylor FB Jr, Peer GT, Lockhart MS, Ferrell G, and Esmon CT.  EPCR plays an important role in protein C activation in vivo. Blood. 2001; 97:1685-1688.

  5. Safa O, Hensley K, Smirnov MD, Merrill JT, D'Angelo A, Esmon CT, and Esmon NL.  Lipid oxidation enhances the function of activated protein C and anti-phospholipid antibodies. J Biol Chem. 2001; 276:1829-1836.

  6. Oganesyan V, Oganesyan N, Terzyan S, Qu D, Dauter Z, Esmon NL, and Esmon CT.   The crystal structure of the endothelial protein C receptor and a bound phospholipid.  J Biol Chem. 2002 Jul 12;277(28):24851-4. Epub 2002 May 28.